Feather, J.

( J. Feather)

patient response myeloma regimen university therapy bortezomib hospital survival treatment study cancer month trial myeloma sk kumar lenalidomide outcome thalidomide diagnosis institute group disease stage transplant table center ﬁ rst regimen factor kumar number event-free survival mayo clinic clinic leukemia result criteria prognostic factors analysis prognostic response rates dexamethasone duration france hematology combination blood rochester serum anderson 5 months hayman sr progression minnesota cancer institute rajkumar department figure spain dispenzieri prince alfred hospital mayo clinic arizona event-free brussel abnormality salamanca agent cell transplantation ﬂ uorescence school iss stage phase boston 0.001 context transplantation range arizona medicine speci oncol

1 Most Recent Publications

Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study (Article)
Kumar, S. Lee, J.H. Leleu, X. Hulin, C. Klein, S.K. Sonneveld, P. Siegel, D. Bladé, J. Goldschmidt, H. Jagannath, S. Miguel, J.S. Orlowski, R.Z. Lahuerta, J.J. Palumbo, A. Sezer, O. Rajkumar, S.V. Durie, B.G.M. Morgan, G. Richardson, P.G. Crowley, J. Haessler, J. Feather, J. Hoering, A. Moreau, P.

2012-01-01

Message*:
Your Email Adress*:
	*: Required fields, please provide an email address so that the RePub team can contact you if needed.